Lancet Oncology

Journal

Publication Venue For

  • Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.  20:570-580. 2019
  • Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.  20:e29-e41. 2019
  • Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.  19:1192-1204. 2018
  • MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.  19:916-929. 2018
  • Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.  19:510-520. 2018
  • Timing of androgen-deprivation therapy in prostate cancer.  18:e634. 2017
  • Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.  18:1373-1385. 2017
  • A step towards predicting checkpoint inhibitor response in kidney cancer.  18:982-983. 2017
  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study.  18:1061-1075. 2017
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.  18:42-51. 2017
  • HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.  17:1435-1444. 2016
  • Cachexia in patients with cancer.  17:e220. 2016
  • Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: Two randomised, active-controlled, double-blind, phase 3 trials.  16:1079-1089. 2015
  • Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: A randomised, active-controlled, double-blind, phase 3 trial.  16:1071-1078. 2015
  • Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study.  16:1025-1036. 2015
  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial 2014
  • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study.  15:1207-1214. 2014
  • Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.  15:1513-1520. 2014
  • RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1.  15:1469-1480. 2014
  • Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: A phase 3, open-label, randomised trial.  14:1326-1336. 2013
  • Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.  14. 2013
  • Subsequent neoplasms of the CNS among survivors of childhood cancer: A systematic review.  14. 2013
  • Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, Single-arm, Phase 2 study.  14:134-140. 2013
  • Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial.  13:1152-1160. 2012
  • Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial.  13:734-742. 2012
  • Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.  13:100-110. 2012
  • Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.  11:21-28. 2010
  • Translating biological insights into clinical endpoints in neuro-oncology.  10:928-929. 2009
  • Preserving function and quality of life after thyroid and parathyroid surgery.  9:1069-1075. 2008
  • Nomograms as clinicobiological predictors of survival in glioblastoma.  9:5-6. 2008
  • Diet, exercise, and complementary therapies after primary treatment for cancer.  7:1017-1026. 2006
  • Genomics-based hypothesis generation: A novel approach to unravelling drug resistance in brain tumours?.  5:89-100. 2004
  • Predicting outcome and tailoring treatment in high-grade gliomas.  4:269-270. 2003
  • Management of terminal cancer in elderly patients.  4:149-157. 2003
  • Brain-tumour drug resistance: The bare essentials.  3:397-406. 2002
  • International Standard Serial Number (issn)

  • 1470-2045
  • Electronic International Standard Serial Number (eissn)

  • 1474-5488